Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

(OSKIRA-Asia-1): A Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose Ranging Study in Asia Evaluating Efficacy and Safety of Fostamatinib in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate Therapy

NCT01569074 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01569074
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01569074 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
(OSKIRA-Asia-1): A Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose Ranging Study in Asia Evaluating Efficacy and Safety of Fostamatinib in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate Therapy
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Terminated
Start date
April 30, 2012
Completion date
July 31, 2013
Enrollment
163 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis